Skip to main content

Fiscal Wizard · Single-issue tearsheet

VRCA / Jun 21, 2026 Run #7287

VRCA

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

Composite verdict

F 24.7 / 100
Bearish setup · Trend Following 11 drivers · 7 gates blocking
  • Rate of Change
  • MACD Signal Cross
  • Parabolic SAR Flip
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 216th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 16 signals100% Bear
Momentum Bearish 0Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Mixed

49.4 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Revenue Growth (YoY) 100
Free Cash Flow Yield 0
Asset Turnover 100
EPS Growth (YoY) 0
Days Sales Outstanding 90
Inventory Turnover 0

Technicals Bearish

0.0 / 100

Bearish setup leads (Rate of Change, MACD Signal Cross, Parabolic SAR Flip); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 8
Parabolic SAR Flip 9
MACD Signal Cross 9

Risk Gates

7 blocking 3 caution

7 guards active, 24 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Beneish M-Score Blocking

Bottom-band Beneish M blocks bullish signals — accounting-quality risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for VRCA.